Viracept Articles
EC reinstates Roche's Viracept
29 October 2007
CHMP recommends Viracept reinstatement
1 October 2007
EC suspends Viracept's marketing license
13 August 2007
Roche
11 June 2007
Roche cuts HIV/AIDS drug prices again
14 June 2004
Vertex/GSK
2 February 2004
Patients prefer Roche's Viracept 625mg
21 July 2003
Roche files for new high-dose Viracept
12 May 2003
AIDS group warns over Roche
17 March 2003
Viracept safe in pregnancy, boosted by food
24 February 2003
New data support efficacy of GW433908
24 February 2003
Roche "no profit" HIV/ AIDS drug deal widens
24 February 2003
New resistance data for B-MS' atazanavir
17 February 2003
Switching to B-MS' atazanavir cuts lipids
22 July 2002
Brazil to step up HIV/ AIDS vaccine R&D
14 January 2002
Initial therapy with Viracept may avoid emergence of HIV "superbugs"
24 December 2001
MSF to export Brazil- made HIV/AIDS drugs
17 September 2001
Roche/Brazil OK 40% Viracept price cut
3 September 2001
Immune Response cancels Remune trial
3 September 2001
Brazil moves on Roche AIDS drug patent
23 August 2001
Roche aims to settle patent dispute with Brazil
17 July 2001
BI's tipranavir effective as HIV salvage regimen
10 July 2001
Brazil plans Viracept compulsory license
27 June 2001
New data for Viracept as first-line therapy
15 June 2001
Brazil prepares to make Roche AIDS drug
23 May 2001
Dip in 1st-qtr pharma sales at Roche
11 April 2001
Canada, Europe give go-ahead to Kaletra
5 April 2001
Merck & Co cuts AIDS drug prices in Brazil
2 April 2001
Merck & Co warning to Brazil over patent
27 March 2001
India OKs Hetero's generic nelfinavir
15 March 2001
Cuba backs Brazil in AIDS drug patent row
7 March 2001
PhRMA warns of pressure to bring reduced HIV/AIDS drug prices to USA
14 February 2001
Brazil challenge to USA over AIDS drugs
6 February 2001
Pfizer forecasts strong revenue growth in 2001-2002 at R&D meeting
14 December 2000
Vertex and GW start pivotal trials of amprenavir prodrug in HIV
29 November 2000
Abbott's HIV drug Kaletra cleared in USA
18 September 2000
Pharma sales drive Roche growth in Q1
13 April 2000
Agouron gets OK for film-coated Viracept
8 March 2000
First clinical data for Agouron's capravirine
2 February 2000
Triangle slumps on FDA request for more Coactinon data
15 December 1999
FDA approves new dose for Agouron's Viracept
2 December 1999
Roche revenues hit 20 billion Swiss francs
14 October 1999
New generation of anti-HIV drugs unveiled at ICAAC
13 October 1999
Remune combo trial
27 September 1999
W-L and Agouron close $2.1 billion merger
18 May 1999
W-L set to acquire Agouron for $2.1 billion
27 January 1999
Tackling lipodystrophy after HIV therapy
26 January 1999
Existing Opportunities In The New HIV/AIDS Treatment Paradigm
16 November 1998
Roche Reports 32% Surge In 9 Months 1998 Sales
12 October 1998
Viracept Aproved in Canada
18 August 1998
Healthy Second-Quarter Growth For US Drug Firms
29 July 1998
Abbott Reports Production Problems For Norvir
28 July 1998
Stock Commentary New York
23 July 1998
First Half Sales At Roche Leap 41%, Boosted By BM
13 July 1998
US Biotech To Break Even By Start Of Millennium?
29 April 1998
Xenical Recommended For Approval By CPMP
16 April 1998
Anti-Infective News In Brief
19 March 1998
Tokyo Stock Comment
12 March 1998
Expanded Warnings For J&J's Hismanal
11 February 1998
EMEA CPMP Plenary Meeting In January
6 February 1998
Promising Data With New GW Therapies
5 February 1998
Immune Response: Remune Combination Trials
29 January 1998
Agouron's Viracept OKed In Europe
29 January 1998
Global Anti-HIV Market To Top $5 Billion In 2005
21 January 1998
FDA Fast Approval Times for NMEs
20 January 1998
Roche Sales Grew 18% In 1997; Pharma Up 15%
16 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
Agouron Shares Hit As Roche Cancer Deal Ends
4 December 1997
Roche's Invirase Confers Survival Benefit
20 October 1997
Combo Therapy With DuPont Merck's Sustiva
20 October 1997
Long-Term Efficacy With Agouron's Viracept
15 October 1997
NDA Filed For New Soft-Gel Saquinavir
9 October 1997
US 2nd Qtr Corporate Results Round-Up
7 August 1997
Performance Still Sought From US Biotech Stocks
21 April 1997
Promising Long-Term Data With Agouron's Viracept
21 April 1997
Agouron Reduces Net Loss Boosted By Viracept
21 April 1997
Stock Comment Tokyo
20 March 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Promise With Agouron's Viracept & Roche's Invirase
3 February 1997
Hoffmann La-Roche To Market Agouron's Viracept
27 January 1997
Vintage Year Ahead For Pharmaceutical Firms?
13 January 1997
Agouron's Viracept To Be Given To Children
13 January 1997
Continued Approval Of Blockbuster Products In '97?
23 December 1996
US Quarterly Results Show Improvements
4 November 1996
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
